The Syneos Health Podcast

Oct 30 2024 149 ep. 21 mins 155
The Syneos Health Podcast artwork

The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.

  Business
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

Oct 30 2024 62 mins  
There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health exper

A Site-Specific Approach to Optimizing Diversity in Oncology Trials

Oct 23 2024 42 mins  
As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syneos Health experts Jane Bentley and Juliette Roberts from our Oncology Therapeutic Strategy & Innovation team, and Kelli Defenbaugh from Patient Recr

Circulating Tumor DNA: Transforming Oncology Clinical Trials

Oct 02 2024 20 mins  
Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial efficiency and patient experience. Unlike traditional tissue biopsies, which sample a single tumor site, ctDNA offers a real-time, comprehens

Cashing in on the Currency of Information

Sep 24 2024 34 mins  
Medical science liaisons—or MSLs—within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering. Only they can share certain types of information with a growing number of medical stakeholders. And only they can bring back medical insights to guide strategic development and brand decisions. Yet, can anyone be certain that this h

Decoding Gen AI’s Potential to Drive More Effective Clinical Trials

Aug 21 2024 31 mins  
AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has already been successfully used in drug discovery. But are we fully leveraging the current AI yet in practical ways? Are our trial designs inf

Connecting the Global Dots on Carbon Footprint in Biopharma

Jul 09 2024 27 mins  
The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, including women, youth, elderly, lower-income groups, and hard-to-reach communities bearing the brunt of this change. We think we know the culprits

Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

May 31 2024 31 mins  
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living with Alzheimer's. Clinical trials for new treatments have faced high failure rates, partly because it's difficult to identify the right patient

Unpacking the Role of Adjuvant Therapies in Breast Cancer

May 23 2024 28 mins  
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, some cancer cells may remain in the body and cause recurrence or metastasis. This is where adjuvant therapies come in: they are additional tr

Site and Study Execution for Ophthalmology Trials

May 08 2024 18 mins  
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potential new medicines for diseases of the eye?In this episode, Nick Kenny, Syneos Health CSO and interim podcast host, is joined by Eileen Schram

The Case for Genetic Medicines

Apr 29 2024 32 mins  
In March 2024, the FDA approved a groundbreaking gene therapy for children with a specific form of leukodystrophy, offering hope to those with no current care options. However, the approval came with a hefty price tag, making headlines as the most expensive medicine in the world at $3,500,000 per patient. With the cost of innovation so high, what can we do to de-risk development, e